Maria Fe Paz, M.Sc, PhD, is, as the Chief Medical Officer (CMO) of the Diaceutics Group. In this capacity she is responsible for the development of clinical and laboratory partnerships. Fe Paz has over 15 years experience in healthcare and biomedical industry, in particularly in epigenetics, pharmacogenetics and molecular diagnostics.
Prior to joining the Diaceutics Group she was head of translational medicine and scientific development in Zeltia SA., a Spanish pharmaceutical company, coordinating international laboratories and hospitals and setting up and managing laboratories for molecular diagnostic-pharmacogenetics.
Fe Paz completed her studies at Johns Hopkins in the US. She lives and works in Mardrid, Spain.
Last Editorial Review: July 9, 2015
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.